| Literature DB >> 34537862 |
Nathaniel Melling1, Daniel Perez1, Julia-Kristin Grass2, Roberto Persiani3, Flavio Tirelli3, Chien-Chih Chen4,5, Marco Caricato6, Alice Pecorino6, Isabelle J Lang1, Marius Kemper1, Jakob R Izbicki1.
Abstract
PURPOSE: Improved long-term survival after low anterior resection (LAR) for rectal cancer highlights the importance of functional outcome. Urogenital and anorectal dysfunction is frequently reported after conventional LAR. Advanced minimally invasive techniques such as robotic (RoTME) and transanal total mesorectal excision (TaTME) might improve functional results by precisely dissecting and preserving autonomic nerves. We compared functional outcomes after RoTME or TaTME in a multicenter study.Entities:
Keywords: Functional outcome; Low anterior resection syndrome; Robotic total mesorectal excision; Transanal total mesorectal excision; Urogenital function
Mesh:
Year: 2021 PMID: 34537862 PMCID: PMC8589758 DOI: 10.1007/s00384-021-04030-5
Source DB: PubMed Journal: Int J Colorectal Dis ISSN: 0179-1958 Impact factor: 2.571
Fig. 1Flowchart of the study populations. Numbers in parentheses indicate female and male patient numbers. OTME, open total mesorectal excision; RoTME, robotic total mesorectal excision; TaTME, transanal total mesorectal excision
Patient characteristics and pathological data
| RoTME (n = 55) | TaTME (n = 65) | p value | |
|---|---|---|---|
| Gender | |||
| Male | 38 (69.1) | 40 (61.5) | 0.387 |
| Female | 17 (30.9) | 25 (38.5) | |
| Age (years) | 59.2 ± 11.9 | 66.6 ± 10.4 | |
| Center | |||
| Hamburg | 41 (74.5) | 0 (0.0) | |
| Rome Campus Biomedico | 0 (0.0) | 15 (23.1) | |
| Taiwan | 14 (25.5) | 1 (1.5) | |
| Rome Gemelli | 0 (0.0) | 49 (75.4) | |
| BMI (kg/m2) | 27.2 ± 5.3 | 25.4 ± 4.0 | 0.381 |
| Previous abdominal surgery | 6 (10.9) | 15 (23.1) | 0.080 |
| Tumor localization (cm) | 6.7 ± 5.3 | 5.5 ± 2.4 | 0.116 |
| Neoadjuvant radiochemotherapy | 18 (32.7) | 41 (63.1) | |
| Tumor stage | |||
| ypT0 | 6 (10.9) | 15 (23.1) | 0.182 |
| pT1 | 13 (23.6) | 10 (15.4) | |
| pT2 | 18 (32.7) | 15 (23.1) | |
| pT3 | 18 (32.7) | 25 (38.5) | |
| Nodal stage | |||
| pN0 | 35 (63.6) | 62 (95.4) | |
| pN1 | 17 (30.9) | 2 (3.1) | |
| pN2 | 2 (3.6) | 1 (1.5) | |
| LN positive (n) | 0.8 ± 1.3 | 0.6 ± 2.2 | 0.519 |
| LN harvested (n) | 16.1 ± 7.9 | 14.2 ± 5.6 | 0.107 |
Numbers indicated as absolute numbers and percentage or mean ± standard deviation; p-values in bold indicate statistically significant differences between surgical techniques
BMI body mass index, LN lymph nodes, n number, p p-value, RoTME robotic total mesorectal excision, TaTME transanal total mesorectal excision
Surgical data
| RoTME (n = 55) | TaTME (n = 65) | p value | |
|---|---|---|---|
| Operative time (min) | 247.0 ± 88.0 | 297.8 ± 85.0 | |
| Estimated blood loss (ml) | 38.9 ± 87.5 | 113.3 ± 252.3 | |
| Procedure | |||
| LAR | 48 (87.3) | 65 (100.0) | |
| APR | 7 (12.7) | 0 (0.0) | |
| Minor complication (Clavien-Dindo 1–2) | 8 (14.5) | 21 (32.3) | |
| Major complication (Clavien-Dindo ≥ 3) | 5 (9.1) | 0 (0.0) | |
| Anastomotic leakage | 4 (8.3)a | 1 (1.5) | 0.117 |
| Resection margin | |||
| R0 | 54 (98.2) | 65 (100.0) | 0.275 |
| Aboral R0 | 55 (100.0) | 65 (100.0) | |
| Aboral margin (mm) | 27.2 ± 23.6 | 10.9 ± 12.3 | |
| CRM R0 | 54 (98.2) | 65 (100.0) | 0.275 |
| CRM margin (mm) | 19.0 ± 15.5 | 4.2 ± 1.3 | |
| Quality of mesorectal excision | |||
| Grad 1 | 36 (90.0) | 56 (87.5) | 0.333 |
| Grade 2 | 3 (7.5) | 8 (12.5) | |
| Grade 3 | 1 (2.5) | 0 (0.0) | |
| Length of hospital stay (d) | 8.5 ± 4.4 | 7.3 ± 4.5 | 0.166 |
| ICU days (d) | 0.7 ± 0.8 | 0.2 ± 0.5 | |
| Readmission (d) | 7 (12.7) | 3 (4.6) | 0.109 |
Numbers indicated as absolute numbers and percentage or mean ± standard deviation; p-values in bold indicate statistical significance between surgical techniques
APR abdominoperineal rectal resection, CRM circumferential resection margin, d days, ICU intensive care unit, LAR low anterior resection, min minute, ml milliliter, n number, p p-value, RoTME robotic total mesorectal excision, TaTME transanal total mesorectal excision
aPercentage of restorative surgery
Fig. 2Anorectal function results measured by LARS and Wexner score. Favorable results are at the lower end of the scale. Numbers indicated as mean ± standard deviation; p-values in bold indicate statistical significance between surgical techniques and are indicated on the figure as *. LARS, low anterior resection syndrome; RoTME, robotic total mesorectal excision; TaTME, transanal total mesorectal excision
Adjusted model for score differences of anorectal und urogenital function
| Difference (mean ± SD) | 95% CI | Difference (mean ± SD) | 95% CI | p-value | Range | Optimum | ||
| Wexner score | 1.0 ± 0.7 | − 0.485–2.545 | 2.7 ± 0.5 | 1.726–3.623 | 0.095 | 0–20 | ⬇ | |
| LARS score | 4.3 ± 2.2 | 0.016–8.604 | 9.8 ± 1.5 | 6.995–12.786 | 0–42 | ⬇ | ||
| ICIQ-MLUTS | 13.8 ± 4.9 | 4.008–23.494 | 1.8 ± 5.8 | − 9.749–13.393 | 1–84 | ⬇ | ||
| IPSS | 5.1 ± 0.9 | 3.287–6.928 | 0.3 ± 1.0 | − 1.677–2.376 | 0–35 | ⬇ | ||
| ICIQ-FLUTS—Filling Score | 1.4 ± 1.7 | − 2.190–4.933 | − 1.1 ± 1.6 | − 4.490–2.293 | 0.050 | 0–15 | ⬇ | |
| ICIQ-FLUTS—Voiding Score | − 1.0 ± 0.7 | − 1.631–1.440 | 0.7 ± 0.8 | − 0.888–2.294 | 0.185 | 0–12 | ⬇ | |
| ICIQ-FLUTS—Incontinence Score | − 0.3 ± 1.0 | − 2.347–2.090 | − 0.2 ± 0.9 | − 2.155–1.664 | 0.844 | 0–20 | ⬇ | |
| IPSS | 0.1 ± 2.2 | − 4.513– − 4.745 | 0.0 ± 1.9 | − 3.972–4.041 | 0.961 | 0–35 | ⬇ | |
| IIEF—erectile function | − 1.5 ± 1.2 | − 3.818–0.881 | − 1.7 ± 1.4 | − 4.462–1.162 | 0.902 | 0–30 | ⬆ | |
| IIEF—orgasmic function | − 3.8 ± 0.6 | − 4.968– − 2.609 | − 2.7 ± − 0.8 | − 4.162– − 1.115 | 0.120 | 0–10 | ⬆ | |
| IIEF—sexual desire | − 1.9 ± 0.5 | − 2.859– − 1.048 | − 1.5 ± 0.6 | − 2.662– − 0.405 | 0.441 | 0–10 | ⬆ | |
| IIEF—satisfaction sexual intercourse | − 3.7 ± 0.7 | − 5.139– − 2.313 | − 2.7 ± 0.9 | − 4.481–0.900 | 0.236 | 0–15 | ⬆ | |
| IIEF—overall satisfaction | − 2.4 ± 0.5 | − 3.349– − 1.419 | − 1.8 ± 0.6 | − 3.033– − 0.719 | 0.368 | 0–10 | ⬆ | |
| IIEF—final score | − 13.4 ± 2.7 | − 18.824– − 7.882 | − 11.7 ± 3.4 | − 13.911–0.052 | 0.615 | 0–75 | ⬆ | |
| FSFI—desire | 0.3 ± 0.6 | − 0.872–1.408 | 0.7 ± 0.7 | − 0.656–2.089 | 0.317 | 1.2–6 | ⬆ | |
| FSFI—arousal | − 0.0 ± 0.8 | − 1.640–1.632 | 0.5 ± 1.0 | − 1.558–2.486 | 0.532 | 0–6 | ⬆ | |
| FSFI—lubrication | 1.4 ± 0.9 | − 0.447–3.174 | 2.6 ± 1.2 | 0.226–4.995 | 0.100 | 0–6 | ⬆ | |
| FSFI—orgasm | 1.2 ± 1.0 | − 0.840–3.247 | 1.7 ± 1.3 | − 0.874–4.356 | 0.516 | 0–6 | ⬆ | |
| FSFI—satisfaction | 0.5 ± 0.8 | − 1.116–2.095 | 1.4 ± 1.0 | − 0.661–3.535 | 0.218 | 0.8–6 | ⬆ | |
| FSFI—pain | 1.9 ± 0.9 | − 0.017–3.842 | 3.8 ± 1.2 | 1.280–6.362 | 0–6 | ⬆ | ||
| Final FSFI | 5.2 ± 4.6 | − 4.335–14.813 | 10.5 ± 6.4 | − 2.783–23.868 | 0.254 | 2.0–36.0 | ⬆ | |
Adjusted linear models for preoperative functional score, BMI, tumor height, radiotherapy, gender for anorectal scores, and for baseline, BMI, tumor height, radiotherapy, restorative surgery for urogenital scores. Values shown as mean ± standard deviation for pre- and postoperative score differences and confidence interval; p-values in bold indicate statistical significance between surgical techniques, and arrows indicate optimum function at upper or lower score range. For anorectal and urinary function, positive difference values indicate a postoperative deterioration, while for sexual function, negative difference values represent a postoperative deterioration
BMI body mass index, CI confidence interval, FSFI Female Sexual Function Index, ICIQ-MLUTS/ICIQ-FLUTS International Consultation on Incontinence—Male/Female Lower Urinary Tract Symptoms Score, IIEF International Index of Erectile Function, LAR low anterior resection, RoTME robotic total mesorectal excision, SD standard deviation, TaTME transanal total mesorectal excision
Fig. 3Urinary function measured by IPSS. Favorable results are at the lower end of the scale. Numbers indicated as mean ± standard deviation; p-values in bold indicate statistical significance between surgical techniques and are indicated on the figure as *. IPSS, International Prostate Symptom Score; RoTME, robotic total mesorectal excision; SD, standard deviation; TaTME, transanal total mesorectal excision
Fig. 4Male sexual function measured by IIEF. Favorable results are at the upper end of the scale. Numbers indicated as mean ± standard deviation; p-values in bold indicate statistical significance between surgical techniques and are indicated on the figure as *. IIEF, International Index of Erectile Function; RoTME, robotic total mesorectal excision; TaTME, transanal total mesorectal excision
Fig. 5Female sexual function measured by FSFI. Favorable results are at the upper end of the scale. Numbers indicated as mean ± standard deviation; p-values in bold indicate statistical significance between surgical techniques and are indicated on the figure as *. FSFI, Female Sexual Function Index; RoTME, robotic total mesorectal excision; TaTME, transanal total mesorectal excision